The efficacy of entecavir therapy in chronic hepatitis B patients with suboptimal response to adevofir

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 7, 2011, Pages 767-774

  Sheen, E ^a   Trinh, H N ^b,c   Nguyen, T T ^d   Do, S T ^e   Tran, P ^f   Nguyen, H A ^b   Nguyen, K K ^b   Garcia, R T ^b,c   Nguyen, M H ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b San Jose Gastroenterology   (United States)

^c Pacific Health Foundation   (United States)

^d Gastroenterology and Hepatology   (United States)

^e Digestive Health Associates of Texas   (United States)

^f Asian Health Village   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; LAMIVUDINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS INHIBITION;

ADENINE; ADULT; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GUANINE; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; REGRESSION ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 80052429042     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04785.x     Document Type: Article

References (32)

1. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6: 1315-41.
2. Lok AS, McMahon BJ,. Chronic hepatitis B. Hepatology 2007; 45: 507-39. (Pubitemid 46374607)
3. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
4. Chen CJ, Iloeje UH, Yang HI,. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis 2007; 11: 797-816. (Pubitemid 350019025)
5. Chen CJ, Yang HI, Iloeje UH,. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009; 49: S72-84.
6. Dienstag JL,. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 2009; 49: S112-21.
7. Nguyen MH, Keeffe EB,. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J Viral Hepat 2009; 16: 149-55.
8. Reijnders JG, Pas SD, Schutten M, de Man RA, Janssen HL,. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol 2009; 50: 674-83.
9. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-7. (Pubitemid 36245756)
10. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16. (Pubitemid 36245757)
11. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81-90. (Pubitemid 38040726)
12. Peters MG, Hann Hw H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91-101. (Pubitemid 38040727)
13. Bristol-Myers Squibb,. Baraclude [Package Insert]. Princeton, NJ: Bristol-Myers Squibb, 2005.
14. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10. (Pubitemid 43357804)
15. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20. (Pubitemid 43357805)
16. Scott LJ, Keating GM,. Entecavir: a review of its use in chronic hepatitis B. Drugs 2009; 69: 1003-33.
17. Colonno RJ, Rose RE, Pokornowski K, et al. Four-year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients. J Hepatol 2007; 46: S294.
18. van Bommel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 73-80.
19. Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V,. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004; 9: 353-63. (Pubitemid 38878751)
20. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WEt,. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10: 625-33. (Pubitemid 41224954)
21. Delaney WEt, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006; 50: 2471-7. (Pubitemid 43993188)
22. Qi X, Xiong S, Yang H, Miller M, Delaney WEt,. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007; 12: 355-62. (Pubitemid 46787980)
23. Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51: 902-11. (Pubitemid 46355274)
24. Villet S, Ollivet A, Pichoud C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007; 46: 531-8. (Pubitemid 46201724)
25. Reijnders JG, Deterding K, Petersen J, et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010; 52: 493-500.
26. Brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41: 1391-8. (Pubitemid 40770292)
27. Villeneuve JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39: 1085-9. (Pubitemid 37523785)
28. Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008; 48: 747-55.
29. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F,. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006; 131: 1253-61. (Pubitemid 44515103)
30. Baldick CJ, Tenney DJ, Mazzucco CE, et al. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology 2008; 47: 1473-82. (Pubitemid 351702731)
31. Guo JJ, Li QL, Shi XF, et al. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naive patient. Antiviral Res 2009; 81: 180-3.
32. Veenstra DL, Sullivan SD, Clarke L, et al. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2007; 25: 963-77. (Pubitemid 350014529)